Evidence map›Paper›PMID 23434765›Full record

ReviewFree radical biology & medicine2014

Regulation of Nrf2-an update.

Suryakant K Niture, Raju Khatri, Anil K Jaiswal

Abstract readReview
In one paragraph

Review in Free radical biology & medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 411 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
411citing papers in PubMed, 3 pooled it
29.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

411 citing papers in PubMed, 3 syntheses or guidelines pooled it, 851 citations in OpenAlex.

  1. Pooled it
  2. The Role of c-Abl in Alzheimer's Disease: Guilty or not Guilty?Cellular and molecular neurobiology · 2025
    Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Pathogenesis of plaque erosion.Trends in cardiovascular medicine · 2026
    Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

351 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Suryakant K NitureDepartment of Pharmacology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Raju KhatriDepartment of Pharmacology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Anil K JaiswalDepartment of Pharmacology, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Electronic address: ajaiswal@som.umaryland.edu.
University of Maryland, Baltimore · US

Funding

REGULATION OF NAD(P)H--QUINONE OXIDOREDUCTASESR01GM047466 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE · PI JAISWAL, ANIL KUMAR · 1997 to 2014
$3.5M
Role and Regulation of INrf2R01ES012265 · NIEHS · UNIVERSITY OF MARYLAND BALTIMORE · PI JAISWAL, ANIL KUMAR · 2005 to 2014
$3.4M
NIEHS NIH HHS R01 ES012265NIEHS NIH HHS R01ES012265NIGMS NIH HHS R01 GM047466NIGMS NIH HHS R01GM047466
6 · The paper itself

Abstract

Nrf2:INrf2 (Keap1) are cellular sensors of oxidative and electrophilic stress. Nrf2 is a nuclear factor that controls the expression and coordinated induction of a battery of genes that encode detoxifying enzymes, drug transporters, antiapoptotic proteins, and proteasomes. In the basal state, Nrf2 is constantly degraded in the cytoplasm by its inhibitor, INrf2. INrf2 functions as an adapter for Cul3/Rbx1 E3 ubiquitin ligase-mediated degradation of Nrf2. Chemicals, including antioxidants, tocopherols including α-tocopherol (vitamin E), and phytochemicals, and radiation antagonize the Nrf2:INrf2 interaction and lead to the stabilization and activation of Nrf2. The signaling events involve preinduction, induction, and postinduction responses that tightly control Nrf2 activation and repression back to the basal state. Oxidative/electrophilic signals activate unknown tyrosine kinases in a preinduction response that phosphorylates specific residues on Nrf2 negative regulators, INrf2, Fyn, and Bach1, leading to their nuclear export, ubiquitination, and degradation. This prepares nuclei for unhindered import of Nrf2. Oxidative/electrophilic modification of INrf2 cysteine 151 followed by PKC phosphorylation of Nrf2 serine 40 in the induction response results in the escape or release of Nrf2 from INrf2. Nrf2 is thus stabilized and translocates to the nucleus, resulting in a coordinated activation of gene expression. This is followed by a postinduction response that controls the "switching off" of Nrf2-activated gene expression. GSK3β, under the control of AKT and PI3K, phosphorylates Fyn, leading to Fyn nuclear localization. Fyn phosphorylates Nrf2 Y568, resulting in nuclear export and degradation of Nrf2. The activation and repression of Nrf2 provide protection against oxidative/electrophilic stress and associated diseases, including cancer. However, deregulation of INrf2 and Nrf2 due to mutations may lead to nuclear accumulation of Nrf2 that reduces apoptosis and promotes oncogenesis and drug resistance.

Indexed as

Transcriptional Activationalpha-TocopherolAnimalsAntioxidantsCarcinogenesisDrug Resistance, NeoplasmHumansIntracellular Signaling Peptides and ProteinsKelch-Like ECH-Associated Protein 1NeoplasmsNF-E2-Related Factor 2Oxidative StressSignal Transductionalpha-TocopherolAntioxidantsIntracellular Signaling Peptides and ProteinsKEAP1 protein, humanKelch-Like ECH-Associated Protein 1NFE2L2 protein, humanNF-E2-Related Factor 2antioxidant-response elementAntioxidantsAREChemoprotectionFree radicalsinhibitor of Nrf2, also known as Keap1INrf2INrf2 (Keap1)NF-E2 related factor 2Nrf2OncogenesisPhytochemicalsreactive oxygen speciesRegulationROSSignalingVitamins

Identifiers

PMID23434765
PMCPMC3773280
OpenAlexW1999718232

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.